New guidelines to evaluate the response to treatment in solid tumors
Explore this paper's citation graph
Summary
A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
- Type
- article
- Published
- 2000-02-02
- Cited by
- 12,597
- References
- 32
- Access
- Open access
- OpenAlex
- https://openalex.org/W2139248078
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:31905278
Keywords
Response Evaluation Criteria in Solid Tumors, Medicine, Set (abstract data type), Medical physics, Process (computing)
References
- An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research.
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
- Historical and methodological developments in clinical trials at the National Cancer Institute.
- WHO Handbook for Reporting Results of Cancer Treatment
- Measuring response in solid tumors: unidimensional versus bidimensional measurement.
- WHO Handbook for Reporting Results of Cancer Treatment
- Reporting results of cancer treatment
- Southwest Oncology Group (SWOG).
- Mount Vernon Hospital
- Treatment
- National Cancer Institute of Canada Clinical Trials Group.
- Reporting results.
- The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology
- From the Food and Drug Administration.
Cited by
- Lung cancer: an evaluation of volumetric histopathological architecture with correlation to computed tomography
- Recurrence patterns of advanced non‐small cell lung cancer treated with gefitinib
- Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
- Chemotherapy in alveolar soft part sarcomas. What do we know?
- Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
- Onkologische Bildgebung zur Beurteilung des Therapieansprechens
- Imaging for oncologic staging and follow-up: review of current methods and novel approaches.
- Imatinib Mesylate
- Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
- 切除不能・再発食道扁平上皮癌に対するsecond-line chemotherapyとしてのDocetaxel/5-fluorouracil/Cisplatin併用療法の検討
- Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.
- Translational research in cancer complementary and alternative medicine: the National Cancer Institute's Best Case Series Program.
- Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
- High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer
- A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma
- Radiologic assessment of rectosigmoid cancer before and after neoadjuvant radiation therapy: comparison between quantitation techniques.
- Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
- Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
- CT, RECIST, and malignant pleural mesothelioma.
- Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Related papers
- Tumor Response Evaluation in Oncology: Current Update
- P-460 Inter-observer variability in tumor response evaluation according to RECIST (Response Evaluation Criteria in Solid Tumors) guidelines
- Evaluation of Tumor Response with RECIST Criteria
- Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
- Revaluation of tumor response evaluation criteria in solid tumors
- New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
- A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.
- Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovariarf Carcinoma?